-
公开(公告)号：WO2022058340A1
公开(公告)日：2022-03-24
申请号：PCT/EP2021/075309
申请日：2021-09-15
申请人： GW RESEARCH LIMITED
摘要： The present invention relates to a method of treating seizures using cannabidiol (CBD), which significantly shortens the dose titration period. This results in patients receiving maintenance doses sooner after initiating treatment, which reduces the occurrence of breakthrough seizures and improves adherence to treatment.
-
2.发明申请
公开(公告)号：WO2022017957A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069898
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with stroke or brain haemorrhage. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence, focal seizures without impairment, focal seizures with impairment and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
公开(公告)号：WO2022017956A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069896
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with herpes simplex virus. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
公开(公告)号：WO2022017949A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069884
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
IPC分类号： A61K31/05 , A61K31/4192 , A61K45/06 , A61P25/08
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients with CHRNA4 gene mutation. In a further embodiment the types of seizures include tonic-clonic, atonic, myoclonic and absence seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
5.发明申请
公开(公告)号：WO2022017945A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069880
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
IPC分类号： A61K31/05 , A61K31/19 , A61K31/4015 , A61K31/551 , A61K45/06 , A61P25/08 , A61K31/4415 , A61K31/5513
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with a SPATA5 mutation. In a further embodiment the types of seizures include tonic, myoclonic and focal seizures with impairment. Preferably the dose of CBD is between mg/kg/day to 50 mg/kg/day.
-
6.发明申请
公开(公告)号：WO2022017940A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069875
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
IPC分类号： A61K31/05 , A61K31/423 , A61K31/53 , A61K31/551 , A61P25/08
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with GPHN mutation. In a further embodiment the types of seizures include tonic and tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
公开(公告)号：WO2022017936A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069868
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
IPC分类号： A61K31/05 , A61K31/19 , A61K31/197 , A61K31/4015 , A61K31/551 , A61K31/165 , A61K31/7048 , A61K31/27 , A61K31/352 , A61K45/06 , A61K31/4192 , A61K31/53 , A61K31/55 , A61P25/08 , A61P25/10 , A61P25/12
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Heterotopia. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, absence and focal seizures without impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
8.发明申请
公开(公告)号：WO2022017926A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069834
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
IPC分类号： A61K31/05 , A61K31/4015 , A61K31/195 , A61K31/551 , A61K31/4166 , A61K31/7048 , A61K45/06 , A61P25/08 , A61P25/12
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
9.发明申请
公开(公告)号：WO2022053486A1
公开(公告)日：2022-03-17
申请号：PCT/EP2021/074661
申请日：2021-09-08
申请人： GW RESEARCH LIMITED
摘要： The present invention relates to the use of cannabidivarin (CBDV) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Rett syndrome. In a further embodiment the types of seizures include focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, and non-motor seizures. Preferably the dose of CBDV is between 2.5 mg/kg/day to 10 mg/kg/day.
-
10.发明申请
公开(公告)号：WO2022017947A1
公开(公告)日：2022-01-27
申请号：PCT/EP2021/069882
申请日：2021-07-15
申请人： GW RESEARCH LIMITED
IPC分类号： A61K31/05 , A61K31/4015 , A61K31/4192 , A61K45/06 , A61P25/08 , A61K36/185
摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with congenital disorder of glycosylation 1P. In a further embodiment the types of seizures include tonic and myoclonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.017 秒)
